SAN JOSE, Calif., Sept. 23, 2019 /PRNewswire/ -- Anixa
Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused
on harnessing the body's immune system to fight cancer, today
announced that Mohummad Siddiqui,
MD, Associate Professor of Surgery at the University of Maryland School of Medicine (UMSOM)
has joined its ongoing prostate cancer Cchek™ study.
UMSOM is one of several sites across the United States participating in this study.
Study enrollment will be led by Dr. Mohummad Siddiqui, who is also the Director of
Urologic Oncology and Robotic Surgery and Chief of Urology at the
Baltimore VA Medical Center.
"We are pleased to be working with Dr. Siddiqui and the
University of Maryland School of
Medicine to further develop our artificial intelligence
based prostate cancer diagnostic test," stated Dr. Amit Kumar, President and CEO of Anixa
Biosciences. "Significant progress has been made in our
efforts to advance the Cchek™ Prostate Cancer Confirmation test
toward commercial launch later this year. We believe the
Cchek™ early cancer detection platform will make a great impact on
patient care, and we are pleased by the continued additions to our
team of collaboration partners."
About Anixa Biosciences, Inc.
Anixa is a
publicly-traded biotechnology company focused on harnessing the
body's immune system in the fight against cancer. Anixa's
therapeutic portfolio includes a cancer vaccine technology focused
on the immunization against α-Lactalbumin to prevent triple
negative breast cancer (TNBC), as well as a cancer immunotherapy
program which uses a novel type of CAR-T, known as chimeric
endocrine receptor t-cell (CER-T) technology. The company's
diagnostic portfolio consists of Cchek™, a liquid biopsy technology
for early detection of solid tumors based on the body's immune
response to the presence of a malignancy. Anixa continually
examines emerging technologies in complementary fields for further
development and commercialization. Additional information is
available at www.anixa.com.
About the University of Maryland School
of Medicine
Now in its third century, the
University of Maryland School of
Medicine was chartered in 1807 as the first public medical
school in the United States. It
continues today as one of the fastest growing, top-tier biomedical
research enterprises in the world, with 43 academic departments,
centers, institutes, and programs. The School of Medicine has a
faculty of more than 3,000 physicians, scientists, and allied
health professionals, including members of the National Academy of
Medicine and the National Academy of Sciences, and a distinguished
recipient of the Albert E. Lasker
Award in Medical Research. With an operating budget of more than
$1.2 billion, the School of Medicine
works closely in partnership with the University of Maryland Medical Center and Medical
System to provide research-intensive, academic and clinically based
care for more than 1.2 million patients each year. The School has
over 2,500 students, residents, and fellows, and nearly
$575 million in extramural funding,
with most of its academic departments highly ranked among all
medical schools in the nation in research funding. As one of the
seven professional schools that make up the University of Maryland, Baltimore campus, the
School of Medicine has a total workforce of nearly 7,000
individuals. The combined School and Medical System ("University of Maryland Medicine") has an annual
budget of over $6 billion and an
economic impact of more than $15
billion on the state and local community. The School of
Medicine faculty, which ranks as the 8th highest among public
medical schools in research productivity, is an innovator in
translational medicine, with 600 active patents and 24 start-up
companies. The School works locally, nationally, and globally, with
research and treatment facilities in 36 countries around the world.
Visit medschool.umaryland.edu.
Forward-Looking Statements: Statements
that are not historical fact may be considered forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are not
statements of historical facts, but rather reflect Anixa's current
expectations concerning future events and results. We
generally use the words "believes," "expects," "intends," "plans,"
"anticipates," "likely," "will" and similar expressions to identify
forward-looking statements. Such forward-looking statements,
including those concerning our expectations, involve risks,
uncertainties and other factors, some of which are beyond our
control, which may cause our actual results, performance or
achievements, or industry results, to be materially different from
any future results, performance, or achievements expressed or
implied by such forward-looking statements. These risks,
uncertainties and factors include, but are not limited to, those
factors set forth in "Item 1A - Risk Factors" and other sections of
our most recent Annual Report on Form 10-K as well as in our
Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.
We undertake no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law. You
are cautioned not to unduly rely on such forward-looking statements
when evaluating the information presented in this press
release.
Anixa contact:
Mike Catelani
mcatelani@anixa.com
408-708-9808
Tiberend Strategic Advisors, Inc.
Sharen Tilman (Investors)
stilman@tiberend.com
646-604-5149
Johanna Bennett (Media)
jbennett@tiberend.com
212-375-2686
View original content to download
multimedia:http://www.prnewswire.com/news-releases/anixa-biosciences-announces-university-of-maryland-school-of-medicine-to-join-cchek-prostate-cancer-study-300922712.html
SOURCE Anixa Biosciences, Inc.